Dolastatin 10

海兔毒素10

Report date: 2023/04/25 13:58:58
NME

Base Information

Drug NameDolastatin 10
Drug Alias NameNSC-376128DLS-10
ClassificationNatural product/ExtractSmall molecules > Synthetic peptide
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsMyelodysplastic SyndromesKidney NeoplasmsProstatic Neoplasms +[11
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesKidney NeoplasmsProstatic Neoplasms +[11

Other Information

ATC CodeN/A
Related LinksKEGG